A molecular signature for oncogenic BRAF in human colon cancer cells is revealed by microarray analysis.

abstract：:With increasing incidence of cancer at most of the sites, and growing economic burden and associated psychological and emotional trauma, it is becoming clearer that more efforts are needed for cancer cure. Since most of the chemotherapeutic drugs are non-selective because they are also toxic to the normal cells, new a...

journal_title：Current cancer drug targets

authors： Kaur M,Agarwal R

更新日期：2007-06-01 00:00:00

abstract：:The greatest risk factor for the development of cervical and other cancers that have been linked to the human papillomavirus (HPV) family is the persistence of the virus. To persist for the decades required to develop HPV-related cancers, the virus must escape host immunity. HPV is a simple DNA virus that has evolved ...

journal_title：Current cancer drug targets

authors： Kanodia S,Fahey LM,Kast WM

更新日期：2007-02-01 00:00:00

abstract：:Haem oxygenase-1 (HO-1) catalyses the rate-limiting step in haem degradation. All three metabolites resulting from haem degradation (carbon monoxide (CO), biliverdin and free iron) have anti-inflammatory and anti-apoptotic properties. HO-1 is a stress-inducible enzyme found extensively expressed in a vast variety of b...

journal_title：Current cancer drug targets

authors： Hjortsø MD,Andersen MH

更新日期：2014-01-01 00:00:00

abstract：:One of the older and most validated cancer treatments is endocrine therapy. Some tumors are dependent on hormone stimulation for growth, and therefore therapeutic interventions aiming to deprive the cells of the hormone are feasible and have been successful. Tumor growth also depends in some cases on growth factors, s...

journal_title：Current cancer drug targets

authors： González G,Lage A

更新日期：2007-05-01 00:00:00

abstract：:Lipophilic derivatives of the anticancer drug paclitaxel (PTX) were prepared by means of its conjugation to lipoamino acid (LAA) residues, with the aim of increasing drug accumulation in tumor cells. PTX was linked to the methyl esters of norleucine (C6) or 2-aminodecanoic acid (C10). A succinic acid group was used as...

journal_title：Current cancer drug targets

authors： Pignatello R,Paolino D,Pantò V,Pistară V,Calvagno MG,Russo D,Puglisi G,Fresta M

更新日期：2009-03-01 00:00:00

abstract：:Angiotensin II (Ang II), a main effector peptide of the renin-angiotensin system (RAS), mediates a hormonal action in the maintenance of blood pressure and electrolyte levels, and thus fluid homeostasis. Ang II also mediates paracrine, autocrine and/or intracrine actions in the control of various specific functions of...

journal_title：Current cancer drug targets

authors： Lau ST,Leung PS

更新日期：2011-05-01 00:00:00

abstract：:Despite advances in multidisciplinary approaches, the prognosis for most patients with malignant gliomas is poor. Malignant gliomas are highly vascularized tumors with elevated expression of vascular endothelial growth factor (VEGF), an important mediator of angiogenesis. Recent studies of bevacizumab, an anti-VEGF mo...

journal_title：Current cancer drug targets

authors： Soffietti R,Trevisan E,Bertero L,Bosa C,Ruda R

更新日期：2012-03-01 00:00:00

abstract：:Angiogenesis is crucial for tumor development and progression, and antiangiogenetic therapy represents a promising approach for cancer treatment. Thus, the in-depth understanding of the molecular mechanism(s) regulating angiogenesis, together with the characterization of molecules expressed by endothelial cells and in...

journal_title：Current cancer drug targets

authors： Fonsatti E,Sigalotti L,Arslan P,Altomonte M,Maio M

更新日期：2003-12-01 00:00:00

abstract：:Actin was first identified in non-muscle cells only about three decades ago, and at about the same time, it was found that actin filaments were disrupted in the malignant transformed cells. The actin network is a rather complex, yet important structural and functional system of all eukaryotic cells. Actin filaments pr...

journal_title：Current cancer drug targets

authors： Rao J,Li N

更新日期：2004-06-01 00:00:00

abstract：BACKGROUND:Oncolytic viruses (OVs), which preferentially infect cancer cells and induce host anti-tumor immune responses, have emerged as an effective melanoma therapy. Tanapoxvirus (TANV), which possesses a large genome and causes mild self-limiting disease in humans, is potentially an ideal OV candidate. Interleukin-...

journal_title：Current cancer drug targets

authors： Zhang T,Kordish DH,Suryawanshi YR,Eversole RR,Kohler S,Mackenzie CD,Essani K

更新日期：2018-01-01 00:00:00

abstract：:NUPR1 is a transcription factor that has attracted great attention because of its various roles in cancer. Several studies were carried out to determine its molecular targets and mechanism of action to develop novel therapies against cancer. Here, we shed light on the role of NUPR1 in different types of cancer. NUPR1 ...

journal_title：Current cancer drug targets

authors： Mansour SMA,Ali SA,Nofal S,Soror SH

更新日期：2020-01-01 00:00:00

abstract：:Exosomes are small vesicles that are secreted by various types of cells, known to mediate signal transduction between cells. During recent years, novel carriers for the delivery of targeted drugs, chemotherapy drugs and RNAs are under development, which is believed to be beneficial for patients. Considering issues of ...

journal_title：Current cancer drug targets

authors： Wang X,Zhang H,Yang H,Bai M,Ning T,Li S,Li J,Deng T,Ying G,Ba Y

更新日期：2018-01-01 00:00:00

abstract：:Bisphosphonates are the standard of care for preventing skeletal morbidity and treating hypercalcemia of malignancy in patients with bone metastases. Zoledronic acid (intravenous; 4 mg monthly) is approved to prevent skeletal-related events (SREs) in patients with bone metastases from several tumor types, and can impr...

journal_title：Current cancer drug targets

authors： Gnant M

更新日期：2009-11-01 00:00:00

abstract：BACKGROUND:Approximately one third of Diffuse Large B cell Lymphomas (DLBCL) are refractory or relapse. Novel therapeutic approaches under scrutiny include inhibitors of B-cell receptor (BCR) signaling. Protein kinase CK2 propels survival, proliferation and stress response in solid and hematologic malignancies and prom...

journal_title：Current cancer drug targets

authors： Mandato E,Nunes SC,Zaffino F,Casellato A,Macaccaro P,Tubi LQ,Visentin A,Trentin L,Semenzato G,Piazza F

更新日期：2018-01-01 00:00:00

abstract：:Anti-angiogenesis therapy is one major approach of cancer therapies nowadays. Unfortunately, anti-angiogenesis therapy targeting VEGF-A was recently stumbled by the drugresistance that results from adaptive mechanisms, such as intratumor hypoxia. To obtain a more efficient therapeutic response, we created and identifi...

journal_title：Current cancer drug targets

authors： Tsai JL,Lee YM,Pan CY,Lee AY

更新日期：2016-01-01 00:00:00

abstract：:The histone deacetylase inhibitors are a new class of cytostatic agents that inhibit the proliferation of tumor cells in culture and in vivo by inducing cell cycle arrest, differentiation and/or apoptosis. Histone acetylation and deacetylation play important roles in the modulation of chromatin topology and the regula...

journal_title：Current cancer drug targets

authors： Vigushin DM,Coombes RC

更新日期：2004-03-01 00:00:00

abstract：:Therapeutic vaccines continue to be one of the most active fields in cancer research. However, despite clear evidence of antitumor effect in laboratory animals, and despite the ability of current vaccine candidates to elicit tumor specific antibodies and T-cells in humans, objective responses in the clinical trials ar...

journal_title：Current cancer drug targets

authors： Gonzalez G,Crombet T,Lage A

更新日期：2011-01-01 00:00:00

abstract：BACKGROUND:Epidermal growth factor receptor (EGFR) is a well-recognised drug target exploited for treating non-small cell lung cancer (NSCLC). Gefitinib and erlotinib are first generation clinically employed inhibitors used against EGFR activating mutants. However, during course of treatment these inhibitors become ine...

journal_title：Current cancer drug targets

authors： Agarwal SM,Pal D,Gupta M,Saini R

更新日期：2017-01-01 00:00:00

abstract：:Inactivation of the FHIT and TP53 genes is frequently observed in primary non-small cell lung cancers (NSCLC) and cell lines and may contribute to resistance to apoptotic stimuli elicited by various anti-tumor drugs. To evaluate a possible relationship between FHIT and TP53 status and response to platinum-analogue reg...

journal_title：Current cancer drug targets

authors： Cortinovis DL,Andriani F,Livio A,Fabbri A,Perrone F,Marcomini B,Pilotti S,Mariani L,Bidoli P,Bajetta E,Roz L,Sozzi G

更新日期：2008-08-01 00:00:00

abstract：:Malignant gliomas are frequently chemoresistant and this resistance seems to depend on at least two mechanisms. First, the poor penetration of many anticancer drugs across the blood-brain barrier (BBB), the blood-cerebrospinal fluid barrier (BCSFB) and blood-tumor barrier (BTB), due to their interaction with several A...

journal_title：Current cancer drug targets

authors： Declèves X,Amiel A,Delattre JY,Scherrmann JM

更新日期：2006-08-01 00:00:00

abstract：:CXCR4 is a chemokine receptor implicated in the metastatic process. The CXCR4 ligand, CXCL12, was shown to bind also the CXCR7 receptor, a recently deorphanized chemokine receptor whose signalling pathway and function are still controversial. This study was conducted to determine patients clinic-pathological factors a...

journal_title：Current cancer drug targets

authors： D'Alterio C,Consales C,Polimeno M,Franco R,Cindolo L,Portella L,Cioffi M,Calemma R,Marra L,Claudio L,Perdonà S,Pignata S,Facchini G,Cartenì G,Longo N,Pucci L,Ottaiano A,Costantini S,Castello G,Scala S

更新日期：2010-11-01 00:00:00

abstract：:Preferentially expressed antigen in melanoma (PRAME) is the best characterized member of the PRAME family of leucine-rich repeat (LRR) proteins. Mammalian genomes contain multiple members of the PRAME family whereas in other vertebrate genomes only one PRAME-like LRR protein was identified. PRAME is a cancer/testis an...

journal_title：Current cancer drug targets

authors： Hermes N,Kewitz S,Staege MS

更新日期：2016-01-01 00:00:00

abstract：:One of the crucial reasons of breast cancer therapy failure is an impairment of mechanisms responsible for metabolism and cellular homeostasis, which makes it difficult to foresee the response to the treatment. Targeted therapy in breast cancer is dictated by the expression of specific molecules such as growth factor ...

journal_title：Current cancer drug targets

authors： Lisiak N,Toton E,Rybczynska M

更新日期：2018-01-01 00:00:00

abstract：:Autophagy is an intracellular lysosomal/vacuolar degradation system, in which the inner cytoplasmic cell membrane is degraded by the lysosomal hydrolases, followed by the resulting products released back into the cytosol. It is involved in many physiological processes which are crucial for cell growth and survival. Ho...

journal_title：Current cancer drug targets

authors： Zhou X,Yue GG,Tsui SK,Pu J,Fung KP,Lau CB

更新日期：2018-01-01 00:00:00

abstract：:Angiogenesis is a key factor in the carcinogenesis process. In oncological practice, angiogenesis inhibition, mainly through the blockade of the VEGF family and its receptors, has been robustly demonstrated to produce clinical benefits and, in specific disease subsets such as colorectal cancer, to extend the overall s...

journal_title：Current cancer drug targets

authors： Bagnasco L,Piras D,Parodi S,Bauer I,Zoppoli G,Patrone F,Ballestrero A

更新日期：2012-05-01 00:00:00

abstract：:The integrin family of cell surface receptors integrates cell-extracellular matrix interactions with the cell cytoskeleton and signalling across the cell membrane, resulting in an important role in cell adhesion, mobility and migration, proliferation, and survival. Changes in the number and identity of integrin recept...

journal_title：Current cancer drug targets

authors： Sheldrake HM,Patterson LH

更新日期：2009-06-01 00:00:00

abstract：:Arsenic trioxide (As2O3) has been used in the clinic for the treatment of acute promyelocytic 1eukemia and some solid tumors. However, its effectiveness against lung cancer has not been well demonstrated, and the underlying mechanism(s) of action remain unclear. In the present study, we found that As2O3 significantly ...

journal_title：Current cancer drug targets

authors： Yang MH,Zang YS,Huang H,Chen K,Li B,Sun GY,Zhao XW

更新日期：2014-01-01 00:00:00

abstract：:AKT is a central signaling molecule in regulating cell survival, proliferation, tumor growth and angiogenesis. Upstream components of AKT signaling pathway such as PI3K, PTEN, and Ras are commonly mutated in many human cancers. Recently it is found that AKT plays an important role in regulating normal vascularization ...

journal_title：Current cancer drug targets

authors： Jiang BH,Liu LZ

更新日期：2008-02-01 00:00:00

abstract：:The application of nanotechnology to biomedical research is expected to have a major impact leading to the development of new types of diagnostic and therapeutic tools. One focus in nanobiotechnology is to develop safe and efficient drug/gene delivery vehicles. Research into the rational delivery and targeting of phar...

journal_title：Current cancer drug targets

authors： Liu Y,Lou C,Yang H,Shi M,Miyoshi H

更新日期：2011-02-01 00:00:00

abstract：:Drugs that target the vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) pathways have revolutionized the treatment of patients with metastatic renal cell cancer (RCC). Patients with clear cell RCC often have mutations or silencing of the von Hippel Lindau gene leading to an accumulati...

journal_title：Current cancer drug targets

authors： Heng DY,Bukowski RM

更新日期：2008-12-01 00:00:00